54 results about "Interstitial cell" patented technology

The application discloses a kind of hepatic organoids containing mesenchyme induction method, belong to organoid culture technical field.The method includes the following steps: (1) human embryonic stem cell WIBR3 pretreatment;(2) utilize human embryonic stem cell WIBR3 and induce liver organoids and mesenchymal cells;(3) mesenchymal cells and liver organoid cells are co-cultured, i.e. obtain the hepatic organoids containing mesenchyme.There is beneficial effect: the application changes the culture mode and method of the hepatic organoids containing mesenchyme.The hepatic organoids containing mesenchyme induction method proposed in the application is simple, and mesenchymal cells and other liver cells have the same genetic background source, suitable for the safety evaluation of drug and other chemical substances, liver fibrosis, non-alcoholic hepatitis modeling and pharmacodynamic evaluation.

The invention discloses application of Gli1 + interstitial cells or SMOC2 protein thereof in diagnosis, treatment and prognosis evaluation of Crohn disease intestinal stenosis. The invention provides application of Gli1 + interstitial cells and SMOC2 protein as targets in preparation of a diagnostic kit or a therapeutic drug for Crohn disease fibrostenosis, and further provides the diagnostic kit for Crohn disease fibrostenosis and the therapeutic drug for Crohn disease fibrostenosis. Meanwhile, the invention further provides application of the reagent for detecting the expression quantity of the SMOC2 in preparation of the kit for evaluating postoperative recurrence of the Crohn disease fibrostenosis and the corresponding kit for evaluating postoperative recurrence of the Crohn disease fibrostenosis. The invention discusses the effect of the Gli1 + interstitial cells in the attack of intestinal fibrostenosis, evaluates the potential of the Gli1 + interstitial cells as a diagnosis and treatment target, and provides a new thought for the treatment of Crohn disease intestinal stenosis.

The invention relates to the technical field of biology, in particular to application of rosa roxburghii tratt active extract in preparation of a medicine for treating dyszoospermia. The extract provided by the invention is prepared from roxburgh rose fruits or roxburgh rose pomace through extraction and enrichment, the raw material resources are rich, the price is low, and the toxic and side effects are low. Animal experiments show that the roxburgh rose active extract has the activity of improving dyszoospermia, and the roxburgh rose active extract can obviously increase the sperm concentration and motility rate of mice with dyszoospermia, reduce the malformation rate and obviously increase the thickness of spermatogenic epithelium, the number of supporting cells and the number of interstitial cells of testicular tissues of the mice with dyszoospermia. WB detection analysis shows that the action way of improving the dyszoospermia by the roxburgh rose active extract is to inhibit activation of an oxidative stress Keap1 / Nrf2 signal channel. The rosa roxburghii tratt active extract has a new function of improving dyszoospermia and can be applied as a medicine for improving dyszoospermia.

The invention relates to the technical field of biological medicine, and discloses rapamycin-loaded microemulsion gel as well as a preparation method and application thereof. The preparation method of the microemulsion gel comprises the following steps: dissolving N, N-dimethyl octadecyl carboxymethyl chitosan in a water phase, then adding an oil phase, a cosurfactant and rapamycin, and stirring to obtain rapamycin-loaded microemulsion; the preparation method comprises the following steps: dissolving a high polymer material in a PBS solution, heating until the high polymer material is completely dissolved, then adding dopamine, stirring for reaction, and finally dialyzing and freeze-drying to obtain the adhesive. And adding a gel matrix containing a thickening agent and an adhesive into the microemulsion, and stirring to obtain the rapamycin-loaded microemulsion gel. According to the prepared microemulsion gel, transdermal drug delivery of hydrophobic drugs is achieved, testis are coated with the microemulsion gel loaded with rapamycin, the blocking effect of damp-heat stress on differentiation and development of testis interstitial cells can be relieved, and the functionality of a male reproduction endocrine system is recovered.

The application provides a WNT5B-promoting tooth differentiation biological product and an application thereof. Compared with the prior art, the application has the following advantages: the patent integrates human embryonic tooth germ spatial transcriptome sequencing and epithelial cell and interstitial cell extracellular protein group sequencing data, screens signal molecules WNT5B and CTNNB1 secreted in the development process of tooth germ epithelium, and confirms the important role of WNT5B protein in tooth germ development for the first time. Compared with other WNT family members, WNT5B has stronger tooth-forming ability of promoting tooth-derived stem cells; the effective concentration of WNT5B is low, and 10 ng / ml is the optimal concentration of WNT5B for promoting tooth-derived stem cells to form teeth; and the role of WNT5B and CTNNB1 in extracellular secretion of tooth germ epithelial cells and the synergistic effect of WNT5B and CTNNB1 in promoting tooth differentiation of tooth germ mesenchymal cells are further determined, that is, the combined low-concentration use effect of the two is better than the single high-concentration use.

The utility model relates to a kind of human adenomyosis ectopic epithelium and stromal cell separation culture devices. The device includes L-shaped base, fixed tube, centrifugal tube, filter separation component. Two centrifugal tubes are used to collect stromal cell and epithelial cell respectively, and the top end of centrifugal tube is connected with top cover. Filter separation component includes mounting ring, locating ring, flexible filter screen, annular frame and positioning mechanism. Mounting ring is horizontally arranged, locating ring is peripherally arranged on mounting ring, and locating ring is adapted to the top end of centrifugal tube, filter screen is arranged at the bottom of mounting ring, the bottom of annular frame is connected with the bottom surface of flexible filter screen, gap is provided between the top of annular frame and mounting ring, and annular frame is limited by positioning mechanism. Compared with prior art, the utility model can simplify the separation process of human adenomyosis ectopic epithelium and stromal cell, reduce cleaning work, and is suitable for laboratory culture operation.

The invention provides a WNT5B dental differentiation promoting biological product and application thereof. Compared with the prior art, the application has the following advantages: by integrating human embryo tooth embryo space transcriptome sequencing data and epithelial cell and interstitial cell exocrine proteome sequencing data, signal molecules WNT5B and CTNNB1 secreted in the tooth embryo epithelial development process are screened out, the important effect of the WNT5B protein in tooth embryo development is confirmed for the first time, and the application has a wide application prospect. Compared with other WNT family members, the WNT5B has higher capability of promoting the tooth formation of the odontogenic stem cells; the onset concentration of the WNT5B is low, and the onset concentration is the optimal concentration of the WNT5B for promoting the odontogenic stem cells to form teeth when the onset concentration is 10ng / ml; the effects of the WNT5B and the CTNNB1 in tooth embryo epithelial cell exocrine and the synergistic effect of the WNT5B and the CTNNB1 in promoting tooth embryo mesenchymal cell odontogenic differentiation are further determined, namely the combined low-concentration use effect of the WNT5B and the CTNNB1 is superior to that of single high-concentration use of the WNT5B and the CTNNB1.

The invention belongs to the field of biological medicine, and relates to application of triptolide in preparation of a medicine for preventing and treating calcified aortic valve diseases. The triptolide is found to be capable of promoting expression and maturation of CTSD and activating enzyme activity of the CTSD, meanwhile, biogenesis of lysosome in valvular interstitial cells can be promoted by regulating and controlling AKT / mTOR / TFEB signal axes, lysosome functions are improved, autophagy flux is recovered, and finally the effect of treating the calcified aortic valve disease is achieved. A novel treatment medicine is provided for the calcified aortic valve disease.

The invention relates to medical application of an asparagine endopeptidase inhibitor in mitral valve mucus-like degeneration, and belongs to the technical field of biological medicine. The invention provides an application of an asparagine endopeptidase inhibitor in preparation of a medicine for treating mitral valve mucus-like degeneration. The invention relates to an application in preparation of a medicine for relieving mitral valve insufficiency. The invention relates to application in preparation of a medicine for inhibiting mitral valve thickening. The invention also discloses an application of the LGMN in preparing a medicine for treating mitral valve mucus-like degeneration by inhibiting the LGMN secreted by the in-situ macrophages. According to the application disclosed by the invention, the LGMN secreted by the macrophages is subjected to targeted antagonism, so that the myofibroblast transformation of the valvular interstitial cells is delayed, and a new target spot and a treatment path are provided for precise treatment of the mitral valve mucus-like degeneration.

This invention belongs to the field of biomedical technology and relates to the application of OSM inhibitors in the preparation of drugs for the prevention or treatment of calcific aortic valve disease. This invention reveals for the first time that OSM drives osteogenic differentiation and calcified nodule formation of valvular interstitial cells through the OSM-OSMR-JAK2 / JAK3-STAT3-RUNX2 signaling axis, which is the core pathogenic mechanism leading to calcific aortic valve disease. This invention utilizes anti-OSM neutralizing antibodies or sulforaphane to effectively block this signaling axis, significantly inhibiting macrophage infiltration, valvular calcification, and improving hemodynamic abnormalities. This invention provides a precise target and a novel strategy for the modification therapy of calcific aortic valve disease, solving the technical problem of the ineffectiveness of traditional broad-spectrum anti-inflammatory therapy in valvular calcification.

The invention relates to the technical field of genetic engineering, in particular to application of PCK1 in preparation of products for regulating and controlling goat testicular interstitial cell proliferation. According to the invention, an over-expression plasmid pcDNA3.1 (+)-PCK1 of the PCK1 gene is constructed, an interference sequence si-PCK1 of the PCK1 gene is synthesized, and it is proposed for the first time that the over-expression of the PCK1 gene can significantly promote the proliferation of goat testicular interstitial cells, and the inhibition of the expression of the PCK1 gene can significantly inhibit the proliferation of the goat testicular interstitial cells. The invention has important significance for improving the development of the goat testis, and provides technical support for researching and developing related products for regulating and controlling the proliferation of the goat testis interstitial cells by taking the PCK1 gene as the target spot.

The invention provides application of disulfiram in preparation of a medicine for treating calcified aortic valve diseases, and belongs to the field of biological medicine. The disulfiram is used for intervening in-vitro cultured valvular interstitial cells and a mouse in-vivo calcified aortic valve stenosis model, and experimental results show that the disulfiram can inhibit the capability of differentiating the valvular interstitial cells to osteogenic phenotypes, relieve extracellular calcification deposition and relieve aortic valve calcification and stenosis. Therefore, the disulfiram can be used as a medicine for treating the calcified aortic valve disease and has a wide application prospect.

The invention discloses application of H-151 in preparation of drugs for preventing and treating calcified aortic valve diseases, relates to the technical field of biological medicines, and is characterized in that the invention provides application of an STING inhibitor H-151 or pharmaceutically acceptable salts thereof in preparation of drugs for preventing and / or treating calcified aortic valve diseases. The invention reveals for the first time that H-151 can inhibit the increase of the expression level of osteogenic differentiation markers ALP and RUNX2 in aortic valve interstitial cells induced by an osteogenic culture medium in an in-vitro experiment, and inhibit osteogenic differentiation and calcium salt deposition of the aortic valve interstitial cells; in addition, aortic valve thickening, fibrosis and calcium salt deposition of mice induced by an aortic valve injury model are inhibited in vivo. Based on the biological effect, the application of H-151 in developing the medicine for treating the calcified aortic valve disease is provided for the first time, and a new technical path and a new medicine choice are provided for preventing and treating the calcified aortic valve disease.

The invention discloses an establishment method and application of an iPSCs (induced pluripotent stem cells)-derived valvular interstitial cell calcification model, and belongs to the technical field of cell model establishment. The construction method of the iPSCs-derived valvular interstitial cell calcification model comprises the following steps: (1) carrying out induced differentiation for 7 days by using the combination of four regulatory factors, namely BMP4, CHIR99021, VEGF and Forskolin, so as to differentiate mature valvular interstitial cells; and (2) culturing the iPSCs-derived valvular interstitial cells in the step (1) in an osteogenic induction culture medium at 37 DEG C under the condition of 5% CO2 for at least 3 days. The invention provides a rapid and efficient differentiation scheme, the mature valvular interstitial cells induced by the scheme are very close to human primary valvular interstitial cells, and a high-quality experimental platform is provided for screening and mechanism research of anti-calcification drugs.

The application discloses a device for predicting the recurrence / metastasis risk of a non-small cell lung cancer patient after operation and application thereof, adopts multiple machine learning algorithms to combine the clinical characteristics, genomic sequencing data and immune microenvironment infiltration characteristics of real world non-small cell lung cancer patients with disease-free survival, and constructs a postoperative recurrence prediction model. Through a Lasso coefficient path diagram, it is confirmed that five characteristics including tumor size, tumor interstitium CD8+ T cell positive rate, tumor parenchyma M2 type tumor-related macrophage positive rate, TP53 gene mutation state and postoperative ctDNA-MRD state are included in model construction, and a MIMIR prediction model is constructed through a random survival forest. The model can help clinicians to accurately evaluate the postoperative disease-free survival of non-small cell lung cancer patients, guide the development of individualized treatment and follow-up schemes, and bring better survival benefits to patients.

The invention relates to the technical field of genetic engineering, in particular to application of miR-145-3p as a target spot in preparation of products for regulating and controlling proliferation of goat testicular interstitial cells. According to the invention, Inhibitor and Mimics sequences taking the miR-145-3p gene as a target spot are constructed, and it is proposed for the first time that overexpression of the miR-145-3p gene can significantly inhibit proliferation of goat testicular interstitial cells, and inhibition of the miR-145-3p gene can significantly promote proliferation of goat testicular interstitial cells. The invention has important significance for improving the development of the goat testis, and provides technical support for researching and developing related products for regulating and controlling the proliferation of the goat testis interstitial cells by taking the miR-145-3p gene as a target spot.

The invention aims to provide a method for separating and amplifying placenta decidua matrix cells in a perinatal period. The method comprises the following steps: adding decidua tissues into a culture medium A containing collagenase for digestion treatment; cleaning to obtain a cell suspension A, and sieving to obtain a cell suspension B; mixing the cell suspension B with a Ficoll solution, and carrying out primary gradient centrifugation; mixing the cell layer and the supernate layer with normal saline, and then carrying out secondary gradient centrifugation; and culturing the cell block mass and the culture medium B in an incubator. According to the method, the success rate of separation and amplification of the placenta decidua interstitial cells in the perinatal period can be increased, the separated and proliferated cells have group cell biomarker expression for tissue repair, and the separation technical method is improved, so that highly purified cells are obtained.

The invention belongs to the technical field of reproductive biology, and particularly provides a method for separating and culturing testicular perichondrial muscle-like cells of an adult mouse. The method comprises the following steps: removing interstitial cells from testis tissues of an adult mouse, and digesting the testis tissues by pancreatin and DNA enzyme to obtain a testis single-cell suspension; and culturing by adopting a new isolated culture medium until the culture dish is full of cells, and carrying out cell passage, cell cryopreservation and resuscitation and cell identification by adopting passage culture mediums with different concentrations. According to the method for separating and culturing the mouse peridermoid cells, the cell separation degree is far higher than that in the prior art, operation is easy, time is saved, the technical blank that the mouse peridermoid cells are difficult to separate and culture is filled, and the method is suitable for large-scale popularization and application. And convenience is provided for research on interaction of the mouse testicular peritubular muscle-like cells with other testicular somatic cells and germ cells.

This invention provides the application of costunolide in the preparation of a drug for preventing posterior capsule opacification. Costunolide effectively reduces posterior capsule opacification after extracapsular lens extraction (ECLE) and exhibits significant anti-inflammatory and anti-fibrotic effects in both in vitro and in vivo models. Mechanistic studies have identified matrix metalloproteinase 8 (MMP8) as a key downstream effector of costunolide, confirming that costunolide inhibits MMP8 expression, thereby blocking the transformation of lens epithelial cells (LECs) into mesenchymal cells and subsequent fibrotic processes. This lays a solid foundation for developing targeted therapies for posterior cataract, a common surgical complication.

The application discloses a method for synchronously marking germ cells and interstitial cells in the testis tissue of Paralichthys olivaceus, which comprises the following steps: cloning MIR17HG-a (long non-coding RNA) of Paralichthys olivaceus by using a probe primer, obtaining a target plasmid after plasmid extraction, carrying out double enzyme digestion and purification to obtain an enzyme-digested plasmid as a probe template, synthesizing Paralichthys olivaceus MIR17HG-a probe by using an SP6 / T7 RNA polymerase, preparing a tissue slice from the testis tissue of Paralichthys olivaceus, and carrying out fluorescent in situ hybridization on the tissue slice by using the Paralichthys olivaceus MIR17HG-a probe, so that the Paralichthys olivaceus MIR17HG-a probe can synchronously mark the germ cells and interstitial cells in the testis tissue of Paralichthys olivaceus. The method solves the defects of traditional marking technology, such as the need for combined marking or multiple step-by-step marking, and fills the blank of synchronous marking of germ cells and interstitial cells in the testis tissue of Paralichthys olivaceus.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of Chipercumin D in preparation of a medicine for treating calcified aortic valve diseases. The core purpose of the invention is to provide a large-scale drug screening method based on Dot-blotting, and the drug is searched for inhibiting osteogenic differentiation of aortic valve interstitial cells and reducing expression of osteogenic specific genes ALP and RUNX2 and formation of calcified nodules, so that the purpose of preventing or treating calcified aortic valve diseases (CAVD) is achieved.

The invention provides a separation method and an identification method of bactrian camel testis interstitial cells, and belongs to the technical field of cell separation. The method comprises the following steps: mixing 0.08-0.12% of collagenase IV solution and 0.23-0.27% of trypsin-EDTA (Ethylene Diamine Tetraacetic Acid) according to a volume ratio of 1: 2, digesting a bactrian camel testis tissue block, then carrying out hypotonic treatment purification to remove redundant germ cells, carrying out differential adhesion purification to remove a large amount of supporting cells, carrying out percoll density gradient centrifugation purification to remove a small amount of supporting cells, and carrying out freeze drying to obtain a finished product. And transferring the suspension with the percoll gradient of 34-60% into a new culture bottle to obtain the interstitial cells with the purity of more than or equal to 95%, and completing identification by combining morphological observation, immunofluorescence staining and secretion function detection. The separated bactrian camel testis interstitial cells can be used for double-hump reproductive performance research, and a foundation is laid for the reproductive performance of bactrian camels.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a succinate dehydrogenase complex B subunit SDHB as a therapeutic target to preparation of drugs for screening and preventing and / or treating aortic valve calcification. The invention proves that the ROR alpha agonist has a protective effect on CAVD through an SDHB-mediated mechanism. In short, succinic acid in the calcified aortic valve is metabolized and accumulated, and in-vitro supplementation of succinic acid promotes osteogenesis and calcification of aortic valve interstitial cells (h-VICs); the overexpression of ROR alpha improves the abnormal mitochondrial metabolism of h-VICs; sDHB is intervened to counteract aortic valve calcification mediated by the ROR alpha agonist to abnormal mitochondrial metabolism. Therefore, as a potential therapeutic target for aortic valve calcification, SDHB can be used for screening and preparing drugs for treating or preventing CAVD, and the technical problem that treatment can only be carried out through a valve replacement operation at present, and an effective drug treatment means is lacked is solved.

The invention discloses a method for synchronously marking germ cells and interstitial cells in paralichthys olivaceus testis tissues, which comprises the following steps: cloning paralichthys olivaceus MIR17HG-a (long non-coding RNA) by using a probe primer, and extracting plasmids to obtain target plasmids; the method comprises the following steps of: synthesizing a paralichthys olivaceus MIR17HG-a probe through SP6 / T7 RNA polymerase, preparing paralichthys olivaceus testis tissues into tissue slices, and performing fluorescence in-situ hybridization on the tissue slices by using the paralichthys olivaceus MIR17HG-a probe, so that the paralichthys olivaceus MIR17HG-a probe can synchronously mark germ cells and interstitial cells in the paralichthys olivaceus testis tissues. The defect that a traditional marking technology needs combined marking or multi-time step-by-step marking is overcome, and the blank of synchronous marking of germ cells and interstitial cells in paralichthys olivaceus testis tissue at present is filled.

The invention relates to a biomarker of periapical cells and application of the biomarker, and belongs to the technical field of biological detection. The objective of the invention is to solve the problem that a conventional periodontal cell marker has expression overlap with other interstitial cells under an anoxic condition, cannot accurately distinguish tip periodontal cell subgroups, and hinders functional research and targeted therapy development thereof. The method comprises the following steps: screening 15 specific genes (including Adamts9, Cd93, Ctla2a, Fkbp1a, Angpt2 and the like) as periapical cell biomarkers by adopting machine learning according to brain single cell sequencing data of a high-altitude hypoxia mouse; and constructing a logistic regression prediction model to realize cell identification. According to the biomarker combination and the biomarker model, the false detection rate (lt; 5%). A new molecular marker for accurately identifying periapical cells is developed through a machine learning method based on a big data set, and a brand new breakthrough is provided for developing hypoxia response type periapical cell specific markers and functional targets.

The application belongs to the technical field of medicine, and particularly relates to a use of a flavonoid compound in aortic valve disease or cardiovascular aging. The flavonoid compound shown in formula I is found to be capable of inhibiting the osteogenic differentiation of valve interstitial cells for the first time. In animal implementation, the flavonoid compound can significantly reduce the peak flow rate and peak pressure difference of the aortic valve of a calcified aortic valve mouse, and has a significant effect of relieving aortic valve calcification. Therefore, the flavonoid compound has a good application prospect in the preparation of a drug for relieving aortic valve disease, relieving cardiovascular aging and other related cardiovascular diseases.

The invention relates to the technical field of probiotics, in particular to a lactic acid bacteria mixture for preventing and delaying heart valve calcification and application of the lactic acid bacteria mixture, and the lactic acid bacteria mixture comprises a saliva combined lactobacillus BR202 strain, a cheese paracasei BR176 strain, a bifidobacterium animalis subsp. Lactis BR621 strain and a plant lactobacillus PQQ-1 strain. According to the invention, human valvular interstitial cells are induced to generate osteogenic differentiation, so as to simulate pathological changes in calcified aortic valve diseases for evaluation, and the results of calcium salt deposition of the human valvular interstitial cells and osteogenic differentiation experiments of the human valvular interstitial cells prove that the human valvular interstitial cells can be used for simulating the pathological changes in the calcified aortic valve diseases. The lactic acid bacteria mixture can effectively delay calcium salt deposition of human valvular interstitial cells and osteogenic differentiation of the human valvular interstitial cells, so that the lactic acid bacteria mixture has the physiological activity function of preventing and delaying cardiac valve calcification, and can be used for preparing medicines or food compositions for preventing and delaying cardiac valve calcification.

The application belongs to the technical field of traditional Chinese medicine, and discloses application of matrine in preparation of a medicine for treating endometriosis and a medicine composition. The matrine used in the application can inhibit proliferation and promote apoptosis of ectopic stromal cells of endometriosis, and can also significantly inhibit metastasis and recurrence of the ectopic stromal cells, and can be widely applied in preparation of medicines for treating endometriosis, and has important clinical value.

The present application relates to a kind of drug based on PARM1 regulation treatment calcified aortic valve disease and its application.The present application first finds that PARM1 is significantly increased in the aortic valve of calcified aortic valve disease (CAVD) patient, and plays a key role in the osteogenic differentiation process of valve interstitial cells (VICs), and the expression level of PARM1 is knocked down can inhibit the osteogenic differentiation of VICs and extracellular calcium salt deposition, reduce aortic valve calcification, and its mechanism of action involves MAPK signal pathway.The present application provides a new target and treatment idea for the treatment of CAVD, and can be applied to related drug research and development and treatment method development.